Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2)
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.04.012
Abstract: Background Certolizumab pegol, the only Fc‐free, PEGylated anti–tumor necrosis factor biologic, demonstrated clinically meaningful improvements suggestive of a positive risk‐benefit balance in phase 2 studies in adults with moderate‐to‐severe chronic plaque psoriasis. Objective Assess certolizumab… read more here.
Keywords: plaque psoriasis; certolizumab; placebo; treatment ... See more keywords